Effect of intramyocardial delivery of autologous bone marrow mononuclear stem cells on the regional myocardial perfusion

Summary

The aim of the sub-study of the MYSTAR randomised trial was to analyse the changes in myocardial perfusion in NOGA-defined regions of interest (ROI) with intramyocardial injections of autologous bone marrow mononuclear cells (BM-MNC) using an elaborated transformation algorithm. Patients with recent first acute myocardial infarction (AMI) and left ventricular (LV) ejection fraction (EF) between 30–45% received BM-MNC by intramyocardial followed by intracoronary injection 68 ± 34 days post-AMI (pooled data of MYSTAR). NOGA-guided endocardial mapping and ^99m-Sestamibi-SPECT (single photon emission computer tomography) were performed at baseline and at three months follow-up (FUP). ROI was delineated as a best polygon by connecting of injection points of NOGA polar maps. ROIs were projected onto baseline and FUP polar maps of SPECT calculating the perfusion severity of ROI. Infarct size was decreased (from 27.2 ± 10.7% to 24.1 ± 11.5%, p<0.001), and global EF increased (from 38 ± 6.1% to 41.5 ± 8.4%, p<0.001) three months after BM-MNC delivery. Analysis of ROI resulted in a significant increase in unipolar voltage (index of myocardial viability) (from 7.9 ± 3.0 mV to 9.9 ± 2.7 mV at FUP, p<0.001) and local linear shortening (index of local wall motion disturbances) (from 11.0 ± 3.9% to 12.7 ± 3.4%, p=0.01). NOGA-guided analysis of the intramyocardially treated area revealed a significantly increased tracer up-take both at rest (from 56.7 ± 16.1% to 62.9 ± 14.2%, p=0.003) and at stress (from 59.3 ± 14.2% to 62.3 ± 14.9%, p=0.01). Patients exhibiting ≥5% improvement in perfusion defect severity received a significantly higher number of intramyocardial BM-MNC. In conclusion, combined cardiac BM-MNC delivery induces significant improvement in myocardial viability and perfusion in the intramyocardially injected area.

Clinical Trials Gov Nr: NCT00384982.

Keywords

Acute myocardial infarction - stem cells, imaging

• References

• 1 Huang PP, Yang XF, Li SZ. et al. Randomised comparison of G-CSF-mobilised peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost 2007; 98: 1335-1342.
• 2 Borchardt T, Braun T. Cardiovascular regeneration in non-mammalian model systems: what are the differences between newts and man?. Thromb Haemost 2007; 98: 311-318.
• 3 Abdel-Latif A, Bolli R, Tleyjeh IM. et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 989-997.
• 4 Lipinski MJ, Biondi-Zoccai GG, Abbate A. et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007; 50: 1761-1767.
• 5 Martin-Rendon E, Brunskill SJ, Hyde CJ. et al. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J 2008; 29: 1807-1818.
• 6 Gyöngyösi M, Lang I, Dettke M. et al. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat Clin Pract Cardiovasc Med 2009; 6: 70-81.
• 7 Gyöngyösi M, Khorsand A, Zamini S. et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 2005; 112 (Suppl. 09) I157-165.
• 8 Nyolczas N, Gyöngyösi M, Beran G. et al. Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study: a multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction. Am Heart J 2007; 153: 212.e1-7.
• 9 Ben-Haim SA, Osadchy D, Schuster I. et al. Nonfluoroscopic, in vivo navigation and mapping technology. Nat Med 1996; 2: 1393-1395.
• 10 Gepstein L, Hayam G, Ben-Haim SA. A novel method for nonfluoroscopic catheter-based electroanatomical mapping of the heart. In vitro and in vivo accuracy results. Circulation 1997; 95: 1611-1622.
• 11 Goldstein S, Ellahham S, Ben-Haim SA. et al. Preliminary animal and clinical experiences using an electromechanical endocardial mapping procedure to distinguish infarcted from healthy myocardium. Circulation 1998; 98: 1116-1124.
• 12 Kornowski R, Hong MK, Gepstein L. et al. Electromechanical mapping for detection of myocardial viability in patients with ischemic cardiomyopathy. Circulation 2001; 103: 1631-1637.
• 13 Gyöngyösi M, Sochor H, Khorsand A. et al. Online myocardial viability assessment in the catheterization laboratory via NOGA electroanatomic mapping: Quantitative comparison with thallium-201 uptake. Circulation 2001; 104: 1005-1011.
• 14 Nekolla SG, Miethaner C, Nguyen N. et al. Reproducibility of polar map generation and assessment of defect severity and extent assessment in myocardial perfusion imaging using positron emission tomography. Eur J Nucl Med 1998; 25: 1313-1321.
• 15 Lunde K, Solheim S, Aakhus S. et al. Autologous stem cell transplantation in acute myocardial infarction: the ASTAMI randomised controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects. Scand Cardiovasc J 2005; 39: 150-158.
• 16 Tendera M, Wojakowski W, Ruzyllo W. et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009; 30: 1313-1321.
• 17 Marenzi G, Bartorelli AL. Improved clinical outcome after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 2007; 28: 2172-2173.
• 18 Wollert KC, Meyer GP, Lotz J. et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004; 364: 141-148.
• 19 Janssens S, Dubois C, Bogaert J. et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006; 367: 113-121.
• 20 Assmus B, Schächinger V, Teupe C. et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002; 106: 3009-3017.
• 21 Schächinger V, Erbs S, Elsässer A. et al. for the REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355: 1210-1221.
• 22 Krause K, Jaquet K, Schneider C. et al. Percutaneous intramyocardial stem cell injection in patients with acute myocardial infarction: first-in-man study. Heart 2009; 95: 1145-1152.
• 23 Losordo DW, Schatz RA, White CJ. et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 2007; 115: 3165-3172.
• 24 Arom KV, Ruengsakulrach P, Jotisakulratana V. Intramyocardial angiogenic cell precursor injection for cardiomyopathy. Asian Cardiovasc Thorac Ann 2008; 16: 143-148.
• 25 Klein HM, Ghodsizad A, Marktanner R. et al. Intramyocardial implantation of CD133+ stem cells improved cardiac function without bypass surgery. Heart Surg Forum 2007; 10: E66-69.
• 26 Bartosik J, El-Ali HH, Nilsson U. et al. Subendocardial versus transmural ischaemia in myocardial perfusion SPECT--a Monte Carlo study. Clin Physiol Funct Imaging 2006; 26: 343-350.
• 27 El-Ali HH, Palmer J, Edenbrandt L. et al. A model that accounts for the interdependence of extent and severity in the automatic evaluation of myocardial defects. Nucl Med Commun 2006; 27: 127-135.